Reproductive Considerations of Gene Therapies for Sickle Cell Disease and Beta-Thalassemia
- Author(s)
- Sorouri, K; Cliff, ERS; Glass, KB; Michaeli, J;
- Details
- Publication Year 2026-01,Volume 48,Issue #1,Page 103179
- Journal Title
- Journal of Obstetrics and Gynaecology Canada
- Publication Type
- Review
- Abstract
- Gene therapies for sickle cell disease and beta-thalassemia offer potentially curative treatment for patients aged ≥12 years but require gonadotoxic myeloablative conditioning. Fertility preservation and hormone replacement are essential components of standard care for ex vivo gene therapies.
- Keywords
- Humans; *beta-Thalassemia/therapy; *Anemia, Sickle Cell/therapy; *Genetic Therapy/adverse effects/methods; Female; *Fertility Preservation/methods; anemia; beta-thalassemia; drug approval; fertility preservation; gene therapy; myeloablative agonists/bone marrow conditioning regimen; sickle cell
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1016/j.jogc.2025.103179
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-01-15 11:50:42
Last Modified: 2026-01-23 05:48:32